ArticleResearch in pharmaceutical sciences2025
Sodium oleate functionalized simvastatin liposomes: boosting endosomal escape and anticancer efficacy in triple negative breast cancer.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Block Copolymer-Sodium Oleate Complexes Through Electrostatic Interactions for Curcumin Encapsulation.Materials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Due to delivery obstacles, Simvastatin, a potential anticancer agent, faces clinical limitations. This study aimed to enhance simvastatin delivery and efficacy against triple-negative breast cancer (TNBC) by developing liposomes modified with sodium oleate (NaOL) to improve endosomal escape. Experimental approach: Simvastatin was encapsulated in 1,2-dimyristoyl-sn-glycero-3-phosphocholine/cholesterol liposomes through thin film hydration. Liposomes with poly(lactic-co-glycolic acid) (PLGA), individually modified with NaOL and PLGA, served as a control endosomal escape enhancer. Formulations were characterized for size, charge, and encapsulation efficiency. Endosomal escape was quantified through subcellular colocalization analysis using confocal microscopy, and anticancer activity was assessed by evaluating cytotoxicity against 4T1 TNBC cells, followed by measurements of intracellular reactive oxygen species (ROS) and DNA damage. Findings/Results: Unmodified liposomes had a size of 115.2 ± 7.94 nm, a zeta potential of -9.67 ± 3.01 mV, and an encapsulation efficiency of 78.93% ± 6.72. NaOL-modified liposomes had a size of 119 ± 9.37 nm, a zeta potential of -31.05 ± 2.38 mV, and an encapsulation efficiency of 84.96% ± 2.51. While PLGA-modified liposomes had a size of 151.1 ± 7.35 nm, zeta potential of -18.68 ± 1.41 mV, and encapsulation efficiency of 83.63% ± 5.56. Importantly, NaOL-liposomes exhibited lower IC Conclusion and Implications: Surface modification with NaOL is a promising strategy to enhance the anticancer efficacy of simvastatin liposomes against TNBC through improved endosomal escape. These encouraging
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.